Destructive effect of RNаse a on the SARS-CoV-2 virus (in vitro research)

Abstract

BACKGROUND: For today, the most important and discussed issue in the professional medical community is the problem of prevention and treatment of a new coronaviral infection (COVID-19). The main reason for the non-decreasing increase in morbidity and mortality is the absence of an etiotropic drug. In our study, it is proposed to use a previously available drug for the treatment of tick-borne encephalitis, ribonuclease A, obtained from the pancreas of cattle.

AIM: The aim of investigation was to study the antiviral activity of RNаse A against SARS-CoV-2 in in vitro experiments.

MATERIALS AND METHODS: The experiment used samples of 50 patients with a confirmed (by PCR) primary diagnosis of a new coronoviral infection COVID-19. The preparation for the study was served by ribonuclease A (neoFroxx GmbH, Germany) at a concentration of 0.5; 1; 5 and 10 mg/ml, incubated at 4 and 37°C, the exposure was 20 minutes, 20 hours. A set of reagents OTT-PCR-RV-SARS-CoV-2 (Syntol, Russia) was used as test systems.

RESULTS: of the current study is the revealed antiviral activity of ribonuclease A at a minmal concentration of 0.5 mg/ml during incubation from 20 minutes to 20 hours, in the temperature range of 4–37°C.

CONCLUSIONS: The data obtained in the in vitro study confirmed the ability of ribonuclease A to destroy viral RNA, which suggests the possible use of the drug both for the treatment of patients and for the treatment of environmental objects.

Keywords

new coronaviral infection / SARS-CoV-2 / COVID-19 / etiotropic agent / ribonuclease A / RNаse

References

[1] Romanov BK. Coronavirus disease COVID-2019. Safety and Risk of Pharmacotherapy. 2020;8(1):3–8. (In Russ.) DOI: 10.30895/2312-7821-2020-8-1-3-8

[2] Романов Б.К. Коронавирусная инфекция COVID-2019 // Безопасность и риск фармакотерапии. 2020. Т. 8, № 1. С. 3–8. DOI: 10.30895/2312-7821-2020-8-1-3-8

[3] Nikiforov VV, Suranova TG, Chernobrovkina TYa, et al. New coronavirus infection (COVID-19): clinical and epidemiological aspects. The Russian Archives of Internal Medicine. 2020;10(2 (52)):87–93. (In Russ.) DOI: 10.20514/2226-6704-2020-10-2-87-93

[4] Никифоров В.В., Суранова Т.Г., Чернобровкина Т.Я. и др. Новая коронавирусная инфекция (COVID-19): клинико-эпидемиологические аспекты // Архивъ внутренней медицины. 2020. Т. 10, № 2(52). С. 87–93. DOI: 10.20514/2226-6704-2020-10-2-87-93

[5] Abaturov AE, Agafonova EA, Krivusha EL, Nikulina A.A. Pathogenesis of COVID-19. Zdorov'e rebenka. 2020;15(2):133–144. (In Russ.). DOI: 10.22141/2224-0551.15.2.2020.200598

[6] Абатуров А.Е., Агафонова Е.А., Кривуша Е.Л., Никулина А.А. Патогенез COVID-19 // Здоровье ребенка. 2020. Т. 15, № 2. С. 133–144. DOI: 10.22141/2224-0551.15.2.2020.200598

[7] Rosenberg HF. RNase A ribonucleases and host defense: an evolving story. J Leukoc Biol. 2008;83(5):1079–1087. DOI: 10.1189/jlb.1107725

[8] Rosenberg H.F. RNase A ribonucleases and host defense: an evolving story // J. Leukoc. Biol. 2008. Vol. 83, No. 5. P. 1079–1087. DOI: 10.1189/jlb.1107725

[9] Abaturov AYe. Ribonucleases А – the most ancient components of nonspecific protection of respiratory tract. Zdorov'e rebenka. 2011;(5(32)):136–142. (In Russ.)

[10] Абатуров А.Е. Рибонуклеазы А — древнейшие компоненты неспецифической защиты респираторного тракта // Здоровье ребенка. 2011. Т. 5, № 32. С. 136–142.

[11] Ilinskaya ON, Shah Mahmud R. Ribonucleases as antiviral agents. Molecular Biology. 2014;48(5):615–623. DOI: 10.1134/S0026893314040050

[12] Ильинская О.Н., Шах Махмуд Р. Рибонуклеазы как противовирусные агенты // Молекулярная биология. 2014. Т. 48, № 5. С. 707. DOI: 10.7868/S0026898414040053

[13] Dyer KD, Rosenberg HF. The RNase a superfamily: generation of diversity and innate host defense. Mol Divers. 2006;10(4):585–597. DOI: 10.1007/s11030-006-9028-2

[14] Dyer K.D., Rosenberg H.F. The RNase a superfamily: generation of diversity and innate host defense // Mol. Divers. 2006. Vol. 10, No. 4. P. 585–597. DOI: 10.1007/s11030-006-9028-2

RIGHTS & PERMISSIONS

Morozov I.A., Godovalov A.P., Oborin D.A.